Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03920995 · ClinicalTrials.gov registry record

Multi-center Database Registry to Study Thalamus Changes Using AI in MS

A clinical trial of Multiple Sclerosis, sponsored by University at Buffalo.

Completed
Registry status
1,000
Enrollment target
1
Study location

NCT03920995 is a study of Multiple Sclerosis that has completed, run by University at Buffalo. The registered enrollment target is 1,000 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (72% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03920995, a study of Multiple Sclerosis, has completed, sponsored by University at Buffalo.

COMPLETED
Registry status
1,000 participants
Enrollment target
1
Study location

Study Summary

In this study the Investigator's propose to validate a newly developed approach, DeepGRAI (Deep Gray Rating via Artificial Intelligence), to simplify the calculation of thalamic atrophy in a clinical routine and allow academic and community neurologists to plan, perform, and publish novel and influential clinical research using data from clinical routine, by employing deep machine learning (DML) pattern recognition (PR) information through use of artificial intelligence (AI).

Conditions Studied

Study Locations (1)

New York

  • University at Buffalo - Buffalo

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2020-04-01
Est. Completion 2023-10-31

Sponsor

University at Buffalo

67 total trials

What the Registry Record Tells You About NCT03920995

The ClinicalTrials.gov registry entry for NCT03920995 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (72% higher). The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT03920995 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03920995 about?

NCT03920995 is a clinical study titled "Multi-center Database Registry to Study Thalamus Changes Using AI in MS". In this study the Investigator's propose to validate a newly developed approach, DeepGRAI (Deep Gray Rating via Artificial Intelligence), to simplify the calculation of thalamic atrophy in a clinical routine and allow academic and community neurologists to plan, perform, and publish novel and influe...

What is the current status of trial NCT03920995?

This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2020-04-01. Estimated completion is 2023-10-31.

What conditions does trial NCT03920995 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT03920995?

This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03920995 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.